The CXCR4 antagonist plerixafor enhances the effect of rituximab in diffuse large B-cell lymphoma cell lines

BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) is an aggressive disease with variable clinical outcome, accounting for at least 25-30 % of adult non-Hodgkin lymphomas. Approximately one third of DLBCL patients are not cured by the currently used treatment regimen, R-CHOP. Hence, new treatment str...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Biomark Res
Päätekijät: Reinholdt, Linn, Laursen, Maria Bach, Schmitz, Alexander, Bødker, Julie Støve, Jakobsen, Lasse Hjort, Bøgsted, Martin, Johnsen, Hans Erik, Dybkær, Karen
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2016
Aiheet:
Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4908729/
https://ncbi.nlm.nih.gov/pubmed/27307990
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40364-016-0067-2
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia